What is the first medication of choice for a patient experiencing persistent monomorphic V-tach?

In the context of managing persistent monomorphic ventricular tachycardia (V-tach), the first medication of choice is lidocaine. Lidocaine is a class 1b antiarrhythmic agent that works primarily by stabilizing the cardiac cell membrane and reducing the cardiac action potential, which contributes to its effectiveness in treating ventricular arrhythmias.

When a patient is experiencing persistent monomorphic V-tach, the heart is beating in a regular but abnormally fast pattern, and it is essential to employ a medication that can quickly restore normal rhythm. Lidocaine is preferred in this scenario because it is specifically effective for ventricular arrhythmias and can act quickly, especially in emergency situations.

While other medications can be useful in different arrhythmias or situations, they are not the first-line treatment for persistent monomorphic V-tach. For example, adenosine is typically used for paroxysmal supraventricular tachycardia rather than monomorphic V-tach. Magnesium sulfate is often used for torsades de pointes and other related arrhythmias, not specifically for persistent monomorphic V-tach. Atropine is primarily indicated for bradycardia and would not be suitable as a first-line treatment in this case.

Thus